Nuvation Bio Inc Revenue per Employee (NUVB), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Nuvation Bio Inc   (NYSE: NUVB)
 

Nuvation Bio Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


With a revenue increase of 251.98% in the third quarter 2026, year on year to cumulative value of $202 million, Nuvation Bio Inc 's revenue per employee grew on a trailing twelve months basis to $ 4,691,419. The productivity of Nuvation Bio Inc 's employees was 0.0%, above the company average.
Within the Healthcare sector Employees of 18 other companies have achieved higher revenue per employee. While Nuvation Bio Inc 's total ranking has deteriorated compared to the previous quarter from 115 to 276. Nuvation Bio Inc has 43 employees.


What is Sales per Employee Ratio?







NUVB Revenue per Employee (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Revenue Change 251.98 % 644.35 % 2683.55 % 544.57 % 5924.06 %
Sales per Employee (TTM) $ 4,691,419 3,943,047 3,305,140 1,439,140 616,581
NUVB's Total Ranking # 276 # 115 # 512 # 498 #
Seq. Revenue Change 41.86 % -61.93 % 98.8 % 227.81 % 200 %


Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 19
Overall Market # 276

Revenue per Employee Statistics
High Average Low
$ 3,943,047 $ 1,646,539 $ 250,814
(Jun 30 2026)   (Mar 31 2025)



Financial Statements
Nuvation Bio Inc 's Revenue MRQ $ 45 Millions Visit NUVB's Income Statement
Nuvation Bio Inc 's Revenues TTM $ 202 Millions Visit NUVB's aggregate revenue growth
What are NUVB's Sales? Visit NUVB's Sales by Segment




Other Ratios
Nuvation Bio Inc 's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
NUVB's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for NUVB's Competitors
Revenue per Employee for NUVB's Suppliers
Revenue per Employee for NUVB's Customers

You may also want to know
NUVB's Sales Growth Rates NUVB's Pe Price to earnings ratio NUVB's Receivables Turnover Ratio NUVB's Stock Quote
NUVB's Net Income Growth Rates NUVB's Ps Price to Sales ratio NUVB's Sales per Employee NUVB's Asset Turnover Ratio
NUVB's Net Margin NUVB's Pb Price to Book ratio NUVB's Financial Strength Ratios NUVB's Dividend Payout Ratio
Date modified: 2026-11-06T13:04:17+00:00




Companies with similar Revenue per Employee for 12 months ending Sep 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Sep 30 2026Number of Employees Sep 30 2026
Ligand Pharmaceuticals Incorporated  5,400,574.47 $ 253.827  Million 47 
Halozyme Therapeutics Inc   4,261,106.38 $ 1,802.448  Million 423 
Ironwood Pharmaceuticals inc   4,002,960.00 $ 400.296  Million 100 
Community Health Systems Inc   3,759,032.26 $ 11,653.000  Million 3,100 
Illumina Inc   3,545,312.50 $ 4,538.000  Million 1,280 
Amgen Inc   2,992,538.46 $ 38,903.000  Million 13,000 
Liquidia Corporation  2,879,004.63 $ 621.865  Million 216 
Kiniksa Pharmaceuticals International Plc  2,584,598.36 $ 945.963  Million 366 
Aurinia Pharmaceuticals Inc   2,513,578.12 $ 321.738  Million 128 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.